teaser
The Committee for Medicinal Products for Human Use of the EMEA has recommended the adoption of a new indication for bevacizumab (Avastin).
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
It is the following: “Avastin in combination with interferon alfa-2a is indicated for first-line treatment of patients with advanced and/or metastatic renal cell cancer.”
Detailed recommendations for the use of this product will be described in the summary of product characteristics which will be available after the variation to the marketing authorisation has been granted by the European Commission.
